Kenderian Saad Sirop, Habermann Thomas M, Macon William R, Ristow Kay M, Ansell Stephen M, Colgan Joseph P, Johnston Patrick B, Inwards David J, Markovic Svetomir N, Micallef Ivana N, Thompson Carrie A, Porrata Luis F, Martenson James A, Witzig Thomas E, Nowakowski Grzegorz S
Division of Hematology, Department of Internal Medicine.
Department of Laboratory Medicine and Pathology, and.
Blood. 2016 Apr 21;127(16):1960-6. doi: 10.1182/blood-2015-08-665505. Epub 2016 Feb 2.
A number of reports have shown a propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL). Long-term data on the incidence and outcomes of transformed NLPHL are lacking. A comprehensive analysis of the actively maintained Mayo Clinic Lymphoma Database was performed. Between 1970 and 2011, 222 consecutive adult patients with new untreated NLPHL were identified. Median age at diagnosis was 40 years, and 146 (66%) were males. The median follow-up was 16 years. Seventeen patients (7.6%) developed a transformation to DLBCL. The median time to transformation was 35 months (range, 6-268 months). Based on the observed 17 transformations during 2304 patient-years of follow-up, the rate of transformation was 0.74 per 100 patient-years. In a multivariate analysis, use of any prior chemotherapy ( ITALIC! P= .04) and splenic involvement ( ITALIC! P= .03) were significantly associated with increased risk of transformation. The 5-year overall survival (OS) in those with transformed disease was 76.4%, and transformation did not adversely affect OS when compared with patients who did not experience transformation. In this large single-institution cohort with long-term follow-up, the risk of transformation was lower than that observed in other low-grade lymphomas.
多项报告显示,结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)有转化为弥漫性大B细胞淋巴瘤(DLBCL)的倾向。目前缺乏关于转化型NLPHL发病率和转归的长期数据。我们对梅奥诊所积极维护的淋巴瘤数据库进行了全面分析。1970年至2011年期间,共确定了222例新诊断的未经治疗的成年NLPHL患者。诊断时的中位年龄为40岁,男性146例(66%)。中位随访时间为16年。17例患者(7.6%)发生了向DLBCL的转化。转化的中位时间为35个月(范围6 - 268个月)。基于2304患者年随访期间观察到的17例转化病例,转化发生率为每100患者年0.74例。多因素分析显示,既往使用过任何化疗(斜体!P = 0.04)和脾脏受累(斜体!P = 0.03)与转化风险增加显著相关。转化型疾病患者的5年总生存率(OS)为76.4%,与未发生转化患者相比,转化并未对总生存率产生不利影响。在这个进行了长期随访的大型单机构队列研究中,转化风险低于其他低级别淋巴瘤。